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Abstract
Objective: To report serial 18F-fluorodeoxyglucose (
18F-FDG) positron emission tomography (PET)/computed
tomography (CT) tumor response following CyberKnife radiosurgery for stage IA non-small cell lung cancer
(NSCLC).
Methods: Patients with biopsy-proven inoperable stage IA NSCLC were enrolled into this IRB-approved study.
Targeting was based on 3-5 gold fiducial markers implanted in or near tumors. Gross tumor volumes (GTVs) were
contoured using lung windows; margins were expanded by 5 mm to establish the planning treatment volumes
(PTVs). Doses ranged from 42-60 Gy in 3 equal fractions.
18F-FDG PET/CT was performed prior to and at 3-6-month,
9-15 months and 18-24 months following treatment. The tumor maximum standardized uptake value (SUVmax) was
recorded for each time point.
Results: Twenty patients with an average maximum tumor diameter of 2.2 cm were treated over a 3-year period.
A mean dose of 51 Gy was delivered to the PTV in 3 to 11 days (mean, 7 days). The 30-Gy isodose contour
extended an average of 2 cm from the GTV. At a median follow-up of 43 months, the 2-year Kaplan-Meier overall
survival estimate was 90% and the local control estimate was 95%. Mean tumor SUVmax before treatment was 6.2
(range, 2.0 to 10.7). During early follow-up the mean tumor SUVmax remained at 2.3 (range, 1.0 to 5.7), despite
transient elevations in individual tumor SUVmax levels attributed to peritumoral radiation-induced pneumonitis
visible on CT imaging. At 18-24 months the mean tumor SUVmax for controlled tumors was 2.0, with
a narrow range of values (range, 1.5 to 2.8). A single local failure was confirmed at 24 months in a patient with an
elevated tumor SUVmax of 8.4.
Conclusion: Local control and survival following CyberKnife radiosurgery for stage IA NSCLC is exceptional. Early
transient increases in tumor SUVmax are likely related to radiation-induced pneumonitis. Tumor SUVmaxvalues return
to background levels at 18-24 months, enhancing
18F-FDG PET/CT detection of local failure. The value of
18F-FDG
PET/CT imaging for surveillance following lung SBRT deserves further study.
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Stereotactic body radiation therapy (SBRT) is an
accepted treatment for inoperable stage I NSCLC [1-12].
Several techniques have been employed to treat these
potentially mobile tumors with relatively tight margins
(5-10 mm). This enhanced accuracy has facilitated the
safe, swift delivery of extremely high radiation doses. As
anticipated, such treatment has improved local control
and overall survival rates relative to historical controls.
However, high peritumoral lung doses have resulted in
focal radiation-induced pneumonitis and fibrosis, ham-
pering the assessment of the tumor response using CT
and
18F-FDG PET imaging [13-17]. To date, a reliable
noninvasive means of detecting early local failure follow-
ing SBRT remains to be established.
In mid-2004 we opened a novel thoracic stereotactic
radiosurgery treatment protocol for patients with inoper-
able small peripheral lung tumors [18,19]. The enhanced
accuracy and flexibility of the CyberKnife [20,21] facili-
tated the safe delivery of dose distributions designed to
eradicate both gross tumor and known microscopic dis-
ease radiating from it [22]. Twenty patients with periph-
eral clinical stage IA NSCLC were treated in 36 months.
As anticipated, given the small tumor size and peripheral
location, both overall surviv a la n dl o c a lc o n t r o lw e r e
excellent. However, such treatment did result in focal
peritumoral pneumonitis and fibrosis, which interfered
with CT tumor response assessment [18,19]. We fol-
lowed this patient cohort for a minimum of 18 months
and evaluated the change in tumor maximum standar-
dized uptake value (SUVmax) following radiosurgery at 3-
6 months, 9-15 months and 18-24 months.
Methods and materials
Eligibility
This study was approved by the hospital institutional
review board. Patients consecutively treated on a single
institution prospective protocol with inoperable
biopsy-proven peripheral clinical stage IA NSCLC
were evaluated. Inoperability was defined as a post-
operative predicted forced expiratory volume in one sec-
ond (FEV1) of less than 40%, post-operative predicted
carbon monoxide diffusing capacity (DLCO) of less than
40%, VO2 max less than 10 ml/kg/min, age greater than
75, or severe comorbid medical conditions. Pure
bronchioloalveolar carcinomas were excluded.
Treatment Planning and Delivery
Patients were treated according to the Georgetown Uni-
versity Hospital small peripheral pulmonary nodule pro-
tocol as previously described [18,19]. Briefly, fine-cut (1-
mm) treatment planning CTs were obtained 7-10 days
after CT-guided percutaneous biopsy and fiducial place-
ment. Gross tumor volumes (GTV) were contoured
utilizing lung windows. The GTV margin was expanded
5 mm to establish the planning treatment volume
(PTV). A treatment plan was generated using the Cyber-
Knife non-isocentric, inverse-planning algorithm with
tissue density heterogeneity corrections for lung. The
radiation dose, ranging from 42-60 Gy in 3 fractions,
was prescribed to an isodose line that covered at least
95% of the PTV and resulted in the 30-Gy isodose con-
tour extending a minimum of 1 cm from the GTV.
Subsequently, patients were brought to the CyberKnife
suite and laid supine on the treatment table with their
arms at their side. Three red light-emitting diodes
(LEDs) were placed on the patient’s anterior torso direc-
ted toward the camera array. Fiducials were located
using the orthogonal x-ray imagers. A correlation model
was created between the LEDs tracked continuously by
the camera array and the fiducial positions imaged peri-
odically by the x-ray targeting system. During treatment
delivery the tumor position was tracked using the live
camera array signal and correlation model; the linear
accelerator was moved by the robotic arm to maintain
precise alignment with the tumor throughout the
respiratory cycle. Fiducials were imaged prior to the
delivery of every third beam to verify targeting accuracy
and to update the correlation model.
Follow-up Studies
Patients were followed per institutional protocol [18,19].
18F-FDG PET/CT imaging was performed prior to and
at 3-6, 9-15 and 18-24 months following radiosurgery.
CT was used for attenuation correction of the PET
emission image data. Quantitative values of tumor meta-
bolic activity were collected by the first author and
expressed as tumor SUV max, defined as the maximum
standardized uptake value within the tumor. Values
were obtained using three-dimensional regions of inter-
est placed on the lung lesions, which were anatomically
defined by combined review of the PET and CT images.
Local tumor recurrence was defined as unequivocal pro-
gression on serial
18F-FDG PET/CT imaging. Biopsy was
required to confirm recurrence.
Statistical Analysis
Data was analyzed and graphs were prepared with the
SPSS 16.02 statistical package. The follow-up duration
was defined as the time from the date of completion of
treatment to the last date of follow-up or the date of
death. Actuarial survival and local control were calcu-
lated from the conclusion of treatment using the
Kaplan-Meier method.
Results
Patient Characteristics
Twenty consecutive predominately older female (4 men
and 16 women) former heavy smokers with biopsy-
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NSCLC not otherwise specified 7 and squamous cell
carcinoma 5) were treated over a 3-year period extend-
ing from January 2005 to January 2008 (Table 1). Sur-
viving patients were followed for a minimum of 18
months without exception.
Treatment Characteristics
The mean maximum tumor diameter was 2.2 cm (range,
1.4 - 3.0 cm) and the mean gross tumor volume (GTV)
was 10 cc (range, 4 - 24 cc). Treatment plans were com-
posed of hundreds of beams shaped using a single circu-
lar collimator (20 to 30 mm in diameter). The mean
dose delivered to the prescription isodose line in three
equal fractions over an average of seven days was 51 Gy
(Table 2). The 30-Gy isodose contour, biologically
equivalent to 50 Gy in 2-Gy fractions, extended an aver-
age of 2 cm from the GTV (range, 1.08 - 2.74 cm).
Disease Spread and Survival
No regional lymph node failures have been observed.
Three patients are alive with distant lung metastases.
Deaths have been attributed to progressive lung dys-
function at 9, 18 and 25 months, respectively. Therefore,
with a median follow-up of 43 months, the 2-year
Kaplan-Meier estimated overall survival is 90% (Figure
1).
Serial change in SUVmax and Local Control
The mean tumor SUVmax before treatment was 6.2
(range, 2.0 to 10.7). Fifty-seven of sixty planned post
treatment
18F-FDG PET/CT studies were completed and
reviewed. At 3-6 months there was a decrease in the
mean tumor SUVmax to 2.3 (range, 1.0 to 5.7), where it
settled for the remainder of the analysis despite fluctua-
tions in some tumors attributed to peritumoral radia-
tion-induced pneumonitis visible on CT imaging (Figure
2). Transient tumor SUVmax elevations, occurring as
early as 3 months following treatment and as high as
5.7, uniformly peaked prior to the 18-24 month
18F-
FDG PET/CT imaging (Figure 3, 4). A single local fail-
ure within the PTV was pathologically confirmed at 24
months in a patient with what appeared to be typical
benign peritumoral lung fibrosis per CT imaging but an
elevated tumor SUVmax of 8.4 (Figure 3, 5). Microscopic
evaluation revealed recurrent tumor infiltrating radia-
tion-induced lung fibrosis (Figure 6) and salvage radio-
frequency ablation (RFA) was completed. Therefore,
with a median follow-up of 43 months, 2-year Kaplan-
Meier estimated local control with CyberKnife radiosur-
gery is 95% (Figure 7.)
Discussion
Prior to initiating the CyberKnife radiosurgery protocol
for inoperable stage IA NSCLC patients, published
reports had documented deficiencies with CT tumor
response assessment following SBRT [13,14]. SBRT
delivered to small peripheral lung tumors with ade-
quate margin damages peritumoral lung tissue and
Table 1 Patient Characteristics
Mean (Range)
Age (years) 75 (64-86)
Weight (lbs) 153 (116-225)
FEV1 (L) 1.12 (0.53-2.48)
% predicted FEV1 59 (21-111)
Table 2 Treatment Characteristics
Mean (Range)
Prescribed Dose (Gy) 51 (42 - 60)
Prescription Isodose Line (%) 80 (75 - 85)
Prescribed Biologic Effective Tumor Dose (BED Gy10) 141 (100-180)
Prescribed Biologic Effective Lung Dose (BED Gy3) 380 (270-460)
Treatment course (days) 7 (3-11)
Figure 1 Kaplan-Meier plot of overall survival.
Figure 2 Change in mean tumor SUVmax.
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of the lung injury typically results in asymptomatic
focal lung parenchyma fibrosis in the region that cor-
responds with the high-dose radiation volume [13,14].
As expected, CT imaging evidence of focal radiation-
induced pneomonitis and fibrosis was consistently
observed within the target volumes of our patients
during follow-up as well [18,19].
18F-FDG PET/CT is
the standard imaging tool for NSCLC at Georgetown
University Hospital. It is both more sensitive and spe-
cific than conventional imaging for the detection of
primary lung tumors, involved regional lymph nodes
and distant metastases [24,25]. Primary lung tumors
with a SUVmax greater than 2.5 are considered malig-
nant until proven otherwise. However, preliminary evi-
dence suggested that like CT imaging,
18F-FDG PET
imaging is limited in assessing local tumor control fol-
lowing SBRT due to early elevations in tumor SUVmax,
which are thought to be related to acute radiation-
induced pneomonitis [15]. Therefore, prior to starting
protocol therapy, the decision was made to routinely
observe inoperable patients with early transient eleva-
tions in tumor SUVmax following radiosurgery.
The mean tumor SUVmax before treatment was 6.2
(range, 2.0 to 10.7), consistent with the small size and
mobility of treated tumors. Study compliance was excel-
lent with 95% of planned surveillance
18F-FDG PET/CT
scans being completed. Although we observed an initial
sharp decline in mean tumor SUVmax to 2.3 followed by
stable mean tumor SUVmax levels during the remainder
of the 18-24 month follow-up, individual tumors fre-
quently showed transient moderate SUVmax elevations
(Figure 3) that were always closely correlated with deliv-
ered radiation dose distributions and CT evidence of
radiation pneumonitis (Figure 4).
18F-FDG PET/CT ima-
ging at 24 months detected our single local recurrence
(Figure 5). High tumor SUVmax alone prompted
immediate biopsy, which confirmed recurrent tumor
infiltrating radiation-induced lung fibrosis (Figure 6).
Following the 18-24 month evaluation no tumor SUV-
max elevations or local failures were identified in this
patient cohort with a median follow-up of 43 months
and excellent survival despite routine
18F-FDG PET/CT
imaging (Figure 7).
In contrast to previous investigations, this study is
reported with both serial imaging and adequate follow-
up [15-17]. Nonetheless, a critical issue concerning its
validity, and the validity of all other currently available
studies like it, merits serious consideration. Routine
biopsy was not justified in this study given the uncertain
clinical significance of early transient elevations in
tumor SUVmax following radiosurgery and the risk asso-
ciated with biopsy in this inoperable patient population
with limited salvage treatment options. Therefore, con-
firmation of radiographic impressions was limited to a
single biopsy in one patient following an increase in
tumor SUVmax; biopsies were not taken to confirm the
absence of the disease in cases in which tumor SUVmax
remained low. Therefore, it is likely that the true local
Figure 3 Individual patient changes in tumor SUVmax.
Figure 4 Right upper lobe clinical stage IA NSCLC treatment
planning PET/CT with a tumor SUVmax of 10.5 (A), planned
radiation dose distribution (B: the planning treatment volume
receiving 45 Gy shown in red and the 30 Gy isodose line in
blue), and PET/CT at 6, 12, and 18 months post-treatment (C, D
and E) show an initial decrease in tumor SUVmax to 1.5
followed by a transient radiation induced increase (tumor
SUVmax = 4.0) which resolves by 18 months (tumor SUVmax =
2.5).
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rate. Furthermore, this difference in local control rates
could be considerable in patients with low pre-treatment
tumor SUVmax values.
Future research, enrolling operable patients with effec-
tive salvage surgery options, will mandate routine
biopsy. These studies will ultimately determine the clini-
cal utility of surveillance
18F-FDG PET/CT imaging fol-
lowing lung radiosurgery. In the interim, it remains our
institutional practice to complete routine serial surveil-
lance
18F-FDG PET/CT imaging following radiosurgery
for stage IA NSCLC to detect local, regional and meta-
static disease.
Conclusions
Local control and survival following CyberKnife radio-
surgery for stage IA NSCLC is exceptional [18,19]. How-
ever, high planned peritumoral lung doses result in
acute radiation induced pneumonitis, which hinders
early
18F-FDG PET/CT tumor response assessment
[12-16]. It appears that tumor SUVmax values return to
background levels at 18-24 months, enhancing
18F-FDG
PET/CT detection of local failure. The value of
18F-FDG
PET/CT imaging for surveillance following lung SBRT
deserves further study.
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